Biogen
BIIB
1,141 hedge funds and large institutions have $52.8B invested in Biogen in 2018 Q4 according to their latest regulatory filings, with 130 funds opening new positions, 374 increasing their positions, 452 reducing their positions, and 123 closing their positions.
4% more funds holding in top 10
Funds holding in top 10: 28 → 29 (+1)
6% more first-time investments, than exits
New positions opened: 130 | Existing positions closed: 123
0% less funds holding
Funds holding: 1,146 → 1,141 (-5)
0.93% less ownership
Funds ownership: 88.17% → 87.24% (-0.93%)
16% less capital invested
Capital invested by funds: $62.8B → $52.8B (-$9.94B)
17% less repeat investments, than reductions
Existing positions increased: 374 | Existing positions reduced: 452
26% less call options, than puts
Call options by funds: $992M | Put options by funds: $1.34B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$492M |
| 2 |
Prudential Financial
Newark,
New Jersey
|
+$135M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$114M |
| 4 |
Parnassus Investments
San Francisco,
California
|
+$94.1M |
| 5 |
AAMU
Amundi Asset Management US
Boston,
Massachusetts
|
+$74.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$208M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$188M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$159M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$154M |
| 5 |
Goldman Sachs
New York
|
-$147M |
BIIB Hedge Fund Activity: Q4 2018 in Review
1,141 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q4 2018, worth a combined $52.8B — down 16% from $62.8B a quarter earlier.
Buyers outnumbered sellers: 130 funds opened new BIIB positions and 123 closed out — a net gain of 7 holders — while 374 added to existing stakes and 452 trimmed.
The largest buyer was Capital World Investors, adding an estimated $492M. The largest seller was Fidelity Investments, cutting an estimated $208M.
- 1,141 institutional investors held Biogen (BIIB) as of Q4 2018, down from 1,146 in Q3 2018.
- Funds reported $52.8B of Biogen stock for Q4 2018, down 16% quarter-over-quarter.
- 130 funds opened new Biogen positions in Q4 2018 and 123 closed out, a net change of +7 holders.
- The largest Biogen buyer in Q4 2018 was Capital World Investors, an estimated $492M added.
- The largest Biogen seller in Q4 2018 was Fidelity Investments, an estimated $208M sold.
Based on aggregated 13F filings for Q4 2018.